Your browser doesn't support javascript.
Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy.
Okada, Yuri; Izumi, Rumiko; Hosaka, Tatsuhiko; Watanabe, Satoshi; Shijo, Tomomi; Hatchome, Naokazu; Konishi, Risa; Ichimura, Yuki; Okiyama, Naoko; Suzuki, Naoki; Misu, Tatsuro; Aoki, Masashi.
  • Okada Y; Department of Neurology.
  • Izumi R; Department of Neurology.
  • Hosaka T; Department of Neurology.
  • Watanabe S; Department of Neurology.
  • Shijo T; Department of Neurology.
  • Hatchome N; Department of Dermatology, Tohoku University School of Medicine, Sendai, Miyagi and.
  • Konishi R; Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Ichimura Y; Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Okiyama N; Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Suzuki N; Department of Neurology.
  • Misu T; Department of Neurology.
  • Aoki M; Department of Neurology.
Rheumatology (Oxford) ; 61(4): e90-e92, 2022 04 11.
Article in English | MEDLINE | ID: covidwho-1546021

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatomyositis / COVID-19 Type of study: Diagnostic study Topics: Long Covid Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatomyositis / COVID-19 Type of study: Diagnostic study Topics: Long Covid Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2022 Document Type: Article